# Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo

> **NCT00258310** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 35 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** capecitabine
- **PROCEDURE:** Surgery, chemotherapy and/or radiotherapy

## Key facts

- **NCT ID:** NCT00258310
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258310, "Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00258310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*